These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 27206386)

  • 1. A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.
    Hannaman D; Dupuy LC; Ellefsen B; Schmaljohn CS
    Vaccine; 2016 Jun; 34(31):3607-12. PubMed ID: 27206386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genetic adjuvant IL-12 enhances the protective efficacy of a DNA vaccine for Venezuelan equine encephalitis virus delivered by intramuscular injection in mice.
    Suschak JJ; Bagley K; Six C; Shoemaker CJ; Kwilas S; Spik KW; Dupuy LC; Schmaljohn CS
    Antiviral Res; 2018 Nov; 159():113-121. PubMed ID: 30268913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates.
    Dupuy LC; Richards MJ; Ellefsen B; Chau L; Luxembourg A; Hannaman D; Livingston BD; Schmaljohn CS
    Clin Vaccine Immunol; 2011 May; 18(5):707-16. PubMed ID: 21450977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Multiagent Alphavirus DNA Vaccine Delivered by Intramuscular Electroporation Elicits Robust and Durable Virus-Specific Immune Responses in Mice and Rabbits and Completely Protects Mice against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenges.
    Dupuy LC; Richards MJ; Livingston BD; Hannaman D; Schmaljohn CS
    J Immunol Res; 2018; 2018():8521060. PubMed ID: 29967804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.
    Coates EE; Edupuganti S; Chen GL; Happe M; Strom L; Widge A; Florez MB; Cox JH; Gordon I; Plummer S; Ola A; Yamshchikov G; Andrews C; Curate-Ingram S; Morgan P; Nagar S; Collins MH; Bray A; Nguyen T; Stein J; Case CL; Kaltovich F; Wycuff D; Liang CJ; Carlton K; Vazquez S; Mascola JR; Ledgerwood JE;
    Lancet Infect Dis; 2022 Aug; 22(8):1210-1220. PubMed ID: 35568049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered Mesenchymal Cells Improve Passive Immune Protection Against Lethal Venezuelan Equine Encephalitis Virus Exposure.
    Braid LR; Hu WG; Davies JE; Nagata LP
    Stem Cells Transl Med; 2016 Aug; 5(8):1026-35. PubMed ID: 27334491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Monovalent and Trivalent MVA-Based Vaccine Completely Protects Mice Against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenge.
    Henning L; Endt K; Steigerwald R; Anderson M; Volkmann A
    Front Immunol; 2020; 11():598847. PubMed ID: 33542715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation.
    Hooper JW; Moon JE; Paolino KM; Newcomer R; McLain DE; Josleyn M; Hannaman D; Schmaljohn C
    Clin Microbiol Infect; 2014 May; 20 Suppl 5():110-7. PubMed ID: 24447183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice.
    Samsa MM; Dupuy LC; Beard CW; Six CM; Schmaljohn CS; Mason PW; Geall AJ; Ulmer JB; Yu D
    Mol Ther; 2019 Apr; 27(4):850-865. PubMed ID: 30770173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.
    Nasar F; Matassov D; Seymour RL; Latham T; Gorchakov RV; Nowak RM; Leal G; Hamm S; Eldridge JH; Tesh RB; Clarke DK; Weaver SC
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel DNA-launched Venezuelan equine encephalitis virus vaccine with rearranged genome.
    Tretyakova I; Tibbens A; Jokinen JD; Johnson DM; Lukashevich IS; Pushko P
    Vaccine; 2019 May; 37(25):3317-3325. PubMed ID: 31072736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN/VEE viruses.
    Paessler S; Ni H; Petrakova O; Fayzulin RZ; Yun N; Anishchenko M; Weaver SC; Frolov I
    J Virol; 2006 Mar; 80(6):2784-96. PubMed ID: 16501087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates.
    Dupuy LC; Richards MJ; Reed DS; Schmaljohn CS
    Vaccine; 2010 Oct; 28(46):7345-50. PubMed ID: 20851089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single center, open label study of intradermal administration of an inactivated purified chick embryo cell culture rabies virus vaccine in adults.
    Recuenco S; Warnock E; Osinubi MOV; Rupprecht CE
    Vaccine; 2017 Aug; 35(34):4315-4320. PubMed ID: 28688782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
    Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
    PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venezuelan equine encephalitis vaccine with rearranged genome resists reversion and protects non-human primates from viremia after aerosol challenge.
    Tretyakova I; Plante KS; Rossi SL; Lawrence WS; Peel JE; Gudjohnsen S; Wang E; Mirchandani D; Tibbens A; Lamichhane TN; Lukashevich IS; Comer JE; Weaver SC; Pushko P
    Vaccine; 2020 Apr; 38(17):3378-3386. PubMed ID: 32085953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.
    Martin SS; Bakken RR; Lind CM; Garcia P; Jenkins E; Glass PJ; Parker MD; Hart MK; Fine DL
    Vaccine; 2010 Apr; 28(18):3143-51. PubMed ID: 20193792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody Preparations from Human Transchromosomic Cows Exhibit Prophylactic and Therapeutic Efficacy against Venezuelan Equine Encephalitis Virus.
    Gardner CL; Sun C; Luke T; Raviprakash K; Wu H; Jiao JA; Sullivan E; Reed DS; Ryman KD; Klimstra WB
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28468884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial.
    Fierro C; Weidenthaler H; Vidojkovic S; Schmidt D; Gafoor Z; Stroukova D; Zwiers S; Müller J; Volkmann A
    Vaccine; 2024 Apr; 42(10):2695-2706. PubMed ID: 38494412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,5-Iodonaphthyl azide-inactivated V3526 protects against aerosol challenge with virulent venezuelan equine encephalitis virus.
    Gupta P; Sharma A; Spurgers KB; Bakken RR; Eccleston LT; Cohen JW; Honnold SP; Glass PJ; Maheshwari RK
    Vaccine; 2016 May; 34(25):2762-5. PubMed ID: 27129427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.